Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DXR 
Daxor Corporation (DXR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: DXR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $23.5
1 Year Target Price $23.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.08% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 55.38M USD | Price to earnings Ratio 69.44 | 1Y Target Price 23.5 |
Price to earnings Ratio 69.44 | 1Y Target Price 23.5 | ||
Volume (30-day avg) 2 | Beta -0.1 | 52 Weeks Range 6.55 - 11.70 | Updated Date 09/11/2025 |
52 Weeks Range 6.55 - 11.70 | Updated Date 09/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.16 |
Earnings Date
Report Date 2025-08-29 | When - | Estimate - | Actual -0.07 |
Profitability
Profit Margin 2710.84% | Operating Margin (TTM) -1509.46% |
Management Effectiveness
Return on Assets (TTM) -2.51% | Return on Equity (TTM) 5.26% |
Valuation
Trailing PE 69.44 | Forward PE - | Enterprise Value 42930072 | Price to Sales(TTM) 835.18 |
Enterprise Value 42930072 | Price to Sales(TTM) 835.18 | ||
Enterprise Value to Revenue 16.81 | Enterprise Value to EBITDA - | Shares Outstanding 4984450 | Shares Floating 2161109 |
Shares Outstanding 4984450 | Shares Floating 2161109 | ||
Percent Insiders 56.64 | Percent Institutions 2.01 |
Upturn AI SWOT
Daxor Corporation
Company Overview
History and Background
Daxor Corporation, founded in 1971, is a medical instrumentation and biotechnology company focused on blood volume measurement technology. It developed and commercialized the BVA-100 Blood Volume Analyzer.
Core Business Areas
- Blood Volume Analysis (BVA): Daxor's primary business revolves around its BVA technology, which measures a patient's blood volume. It offers the BVA-100 instrument, consumables (reagents and supplies), and related services such as training and quality control.
Leadership and Structure
Daxor is led by a board of directors and executive management team. Dr. Joseph Feldschuh is the CEO and President.
Top Products and Market Share
Key Offerings
- BVA Consumables and Services: Includes reagents, quality control materials, and training and maintenance services required to operate the BVA-100. Market share data unavailable. Competitors are other diagnostic reagent and service providers.
- BVA-100 Blood Volume Analyzer: The BVA-100 is Daxor's flagship product. It is used to measure a patient's blood volume. Market share data is difficult to pinpoint exactly because this device is very niche. Competing technologies exist, but are not direct substitutes, and include things like clinical assessments, or more involved (and risky) invasive procedures. Competitors include companies producing alternative diagnostics, or companies focused on treating fluid imbalances.
Market Dynamics
Industry Overview
The market for blood volume analysis is relatively niche. Daxor operates in the medical diagnostics industry, where technological advancements, regulatory approvals, and reimbursement policies are key drivers.
Positioning
Daxor is a specialized player in the blood volume analysis niche. Its competitive advantage stems from its proprietary BVA technology, which provides direct and precise blood volume measurements. This offers a distinct advantage in situations where accurate blood volume data is needed.
Total Addressable Market (TAM)
The TAM is difficult to quantify, but encompasses all patients who may benefit from accurate blood volume assessment. Daxor's positioning is focused on expanding its reach within specific medical specialties.
Upturn SWOT Analysis
Strengths
- Proprietary BVA technology
- Specialized focus on blood volume analysis
- Established customer base
- Experienced leadership
Weaknesses
- Limited product portfolio
- High reliance on a single product
- Small company size
- Limited marketing and sales reach
- Dependence on hospital capital expenditure budgets
Opportunities
- Expanding applications of BVA technology into new medical specialties (e.g., heart failure, nephrology)
- Gaining regulatory approvals for new BVA indications
- Strategic partnerships with medical device companies
- International expansion
- Increased awareness of the importance of accurate volume management
Threats
- Emergence of competing blood volume analysis technologies
- Changes in reimbursement policies
- Economic downturns affecting hospital budgets
- Regulatory hurdles
- Product liability risks
Competitors and Market Share
Key Competitors
Competitive Landscape
Daxor faces competition from medical device companies offering alternative diagnostic methods and technologies for fluid management. Daxor's competitive advantage lies in its proprietary BVA technology, providing a more precise and direct measurement of blood volume.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require analysis of past financial reports and SEC filings.
Future Projections: Future growth is dependent on successful commercialization of BVA technology in new markets and gaining regulatory approvals. Analyst estimates are not readily available as it is a small company.
Recent Initiatives: Recent initiatives depend on the company's latest strategic announcements and can be found in press releases and investor presentations.
Summary
Daxor is a niche player in the medical diagnostics industry with its proprietary BVA technology. The company's reliance on a single product and small size poses limitations. Opportunities exist in expanding BVA applications and international markets. However, the company must navigate threats such as competition and regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q)
- Daxor Corporation website
- Industry reports and publications
Disclaimers:
This analysis is based on publicly available information and should not be considered investment advice. The financial data is illustrative and requires retrieval from recent SEC filings. Market share data is estimated and may not be precise. The AI-based rating is a general assessment and should be used with caution.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Daxor Corporation
Exchange NASDAQ | Headquaters Oak Ridge, TN, United States | ||
IPO Launch date 1992-03-17 | Chairman, President & CEO Mr. Michael Richard Feldschuh | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees - | Website https://www.daxor.com |
Full time employees - | Website https://www.daxor.com | ||
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.